Amikacin Sulfate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Amikacin Sulfate |
| DrugBank ID | DB00479 |
| Brand Names (EU) | Arikayce liposomal |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.82% |
Approved Indication (EMA)
Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | paratyphoid fever | 99.82% | DL |
| 2 | diffuse scleroderma | 99.82% | DL |
| 3 | punctate epithelial keratoconjunctivitis | 99.80% | DL |
| 4 | typhoid fever | 99.77% | DL |
| 5 | epiglottitis | 99.74% | DL |
| 6 | salmonellosis | 99.74% | DL |
| 7 | bacterial meningitis | 99.65% | DL |
| 8 | congenital analbuminemia | 99.64% | DL |
| 9 | polyclonal hyperviscosity syndrome | 99.62% | DL |
| 10 | hyperamylasemia | 99.62% | DL |
| 11 | meningococcemia | 99.58% | DL |
| 12 | staphylococcal pneumonia | 99.53% | DL |
| 13 | neurotrophic keratopathy | 99.48% | DL |
| 14 | exposure keratitis | 99.41% | DL |
| 15 | bacterial arthritis | 99.40% | DL |
| 16 | blood group incompatibility | 99.39% | DL |
| 17 | gingivitis | 99.36% | DL |
| 18 | bacterial pneumonia | 99.33% | DL |
| 19 | premalignant hematological system disease | 99.29% | DL |
| 20 | pneumococcal meningitis | 99.27% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.